Differential diagnosis of acute dyspnea: The value of B natriuretic peptides in the emergency department

QJM: An International Journal of Medicine

Volumn 101, Issue 11, 2008, Pages 831-843

  Ray, Patrick ^a   Delerme, S ^a   Jourdain, P ^b   Chenevier Gobeaux, C ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Groupe Hospitalier Pitié Salpêtrière ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; FIBRINOLYTIC AGENT;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DYSPNEA; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; EMERGENCY CARE; EMERGENCY WARD; HORMONE RELEASE; HOSPITAL DISCHARGE; HOSPITALIZATION COST; HUMAN; KIDNEY DYSFUNCTION; LUNG EMBOLISM; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

EID: 54949095464     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn080     Document Type: Review

References (83)

1. McCaig LF, Burt CW. National Hospital Ambulatory Medical Care Survey: 2002 emergency department summary. Adv Data 2004; 1-34.
2. Lien CT, Gillespie ND, Struthers AD, McMurdo ME. Heart failure in frail elderly patients: Diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. Eur J Heart Fail 2002; 4:91-8.
3. Mueller C, Frana B, Rodriguez D, Laule-Kilian K, Perruchoud AP. Emergency diagnosis of congestive heart failure: Impact of signs and symptoms. Can J Cardiol 2005; 21:921-4.
4. Rihal CS, Davis KB, Kennedy JW, Gersh BJ. The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol 1995; 75:220-3.
5. Jorge S, Becquemin MH, Delerme S, Bennaceur M, Isnard R, Achkar R, et al. Cardiac asthma in elderly patients: Incidence, clinical presentation and outcome. BMC Cardiovasc Disord 2007; 7:16.
6. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347 161-7.
7. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647-54.
8. Chenevier-Gobeaux C, Allo JC, Arthaud M, Achkar R, Claessens YE, Ekindjian OG, et al. NT-proBNP testing for short-term prognosis in breathless elderly patients. Am J Emerg Med 2008; 26:555-60.
9. Fischer JE, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: Clinical example of sepsis. Intensive Care Med 2003; 29:1043-51.
10. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994; 271:703-7.
11. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28:89-94.
12. Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006; 290:H17-29.
13. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90 195-203.
14. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-28.
15. Maisel AS. The diagnosis of acute congestive heart failure: Role of BNP measurements. Heart Fail Rev 2003; 8:327-34.
16. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 24:341-56.
17. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007; 12:131-42.
18. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007; 49:1193-202.
19. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007; 49:1071-8.
20. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002; 316:129-35.
21. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003; 334:233-9.
22. Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 2005; 102:17442-7.
23. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005; 26:1044-59.
24. Austin WJ, Bhalla V, Hernandez-Arce I, Isakson SR, Beede J, Clopton P, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126:506-12.
25. Kroll MH, Twomey PJ, Srisawasdi P. Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. Clin Chim Acta 2007; 380:197-202.
26. Clerico A, Lervasi G, Del Chicca MG, Emdin M, Maffei S, Nannipieri M, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998; 21:170-9.
27. Suttner SW, Boldt J. Natriuretic peptide system: Physiology and clinical utility. Curr Opin Crit Care 2004; 10:336-41.
28. Emdin M, Passino C, Del Ry S, Prontera C, Galetta F, Clerico A. Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. Clin Chem Lab Med 2003; 41 686-92.
29. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5:599-606.
30. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, et al Impact of body mass and body composition on circulating levels of natriuretic peptides: Results from the Dallas Heart Study. Circulation 2005; 112:2163-8.
31. Hermann-Arnhof KM, Hanusch-Enserer U, Kaestenbauer T, Publig T, Dunky A, Rosen HR, et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: Comparison with patients in different stages of heart failure. Clin Chem 2005; 51:138-43.
32. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135:825-32.
33. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, et al Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343:440-4.
34. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-40.
35. Ray P, Birolleau S, Lefort Y, Becquemin MH, Beigelman C, Isnard R, et al. Acute respiratory failure in the elderly: Etiology, emergency diagnosis and prognosis. Crit Care 2006; 10:R82.
36. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106 416-22.
37. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. Eur J Heart Fail 2005; 7 537-41.
38. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95 948-54.
39. Alibay Y, Beauchet A, El Mahmoud R, Schmitt C, Brun-Ney D, Benoit MO, et al. Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomed Pharmacother 2005; 59:20-4.
40. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, Lopez L, Cotes C, Bellido J, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004; 6 301-8.
41. Berdague P, Caffin PY, Barazer I, Vergnes C, Sedighian S, Letrillard S, et al. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. Am Heart J 2006; 151:690-8.
42. Cabanes L, Richaud-Thiriez B, Fulla Y, Heloire F, Vuillemard C, Weber S, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001; 120:2047-50.
43. Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D, Ekindjian OG. Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the Emergency Department: Comparison with brain natriuretic peptide (BNP). Clin Chim Acta 2005; 361:167-75.
44. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37:379-85.
45. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42:728-35.
46. Logeart D, Saudubray C, Beyne P, Thabut G, Ennezat PV, Chavelas C, et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol 2002; 40:1794-800.
47. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005; 91:606-12.
48. Ray P, Arthaud M, Birolleau S, Isnard R, Lefort Y, Boddaert J, et al Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J Am Geriatr Soc 2005; 53:643-8.
49. Ray P, Arthaud M, Lefort Y, Birolleau S, Beigelman C, Riou B. Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med 2004; 30:2230-6.
50. Zaninotto M, Mion M, Altinier S, Pastorello M, Rocco S, Tosato F, et al. NT-proBNP in the differential diagnosis of acute dyspnea in the emergency department. Clin Biochem 2005; 38:1041-4.
51. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006; 47:91-7.
52. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41:571-9.
53. Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet 2002; 360:1631-9.
54. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J 2007.
55. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47:76-84.
56. Arques S, Roux E, Sbragia P, Ambrosi P, Pieri B, Gelisse R, et al. B-type natriuretic peptide and tissue Doppler study findings in elderly patients hospitalized for acute diastolic heart failure. Am J Cardiol 2005; 96:104-7.
57. Knudsen CW, Riis JS, Finsen AV, Eikvar L, Muller C, Westheim A, et al Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: Effect of age and gender. Eur J Heart Fail 2004; 6:55-62.
58. Coste J, Jourdain P, Pouchot J. A gray zone assigned to inconclusive results of quantitative diagnostic tests: Application to the use of brain natriuretic peptide for diagnosis of heart failure in acute dyspneic patients. Clin Chem 2006; 52:2229-35.
59. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008; 101 29-38.
60. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004; 10:1-30.
61. Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction: Diagnostic and prognostic impact of cardiac tropo nins and natriuretic peptides. Chest 2006; 129:1349-66.
62. Knudsen CW, Clopton P, Westheim A, Klemsdal TO, Wu AH, Duc P, et al Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: An analysis from the breathing not properly multinational study. Ann Emerg Med 2005; 45 573-80.
63. Arnold JM, Howlett JG, Dorian P, Ducharme A, Giannetti N, Haddad H, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007; 23:21-45.
64. Alibay Y, Beauchet A, El Mahmoud R, Brun-Ney D, Alexandre JA, Benoit MO, et al. Analytical correlation between plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in patients presenting with dyspnea. Clin Biochem 2004; 37:933-6.
65. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115:3103-10.
66. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49:1733-39.
67. Green SM, Redmond P, Januzzi JL, Aleryani S, Lee-Lewandrowski E, Sluss P, et al. The impact of aminoterminal pro-brain natriuretic peptide testing on hospital length of stay and morbidity in patients with acute decompensated heart failure. Arch Pathol Lab Med 2007; 131:473-6.
68. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355 1126-30.
69. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG, et al. NTproBNP-guided drug treatment for chronic heart failure: Design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 2006; 8:532-8.
70. Bayes-Genis A, Lopez L, Zapico E, Cotes C, Santalo M, Ordonez-Llanos J, et al. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail 2005; 11:S3-8.
71. Gegenhuber A, Mueller T, Dieplinger B, Poelz W, Pacher R, Haltmayer M. B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. Clin Chim Acta 2006; 370:174-9.
72. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39:131-8.
73. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: An international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27:330-7.
74. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43:635-41.
75. Christ M, Laule K, Klima T, Hochholzer W, Breidthardt T, Perruchoud AP, et al. Multimarker strategy for risk prediction in patients presenting with acute dyspnea to the emergency department. Int J Cardiol 2007.
76. Cournot M, Leprince P, Destrac S, Ferrieres J. Usefulness of in-hospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure. Am J Geriatr Cardiol 2007; 16:8-14.
77. Verdiani V, Nozzoli C, Bacci F, Cecchin A, Rutili MS, Paladini S, et al. Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail 2005; 7:566-71.
78. Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation 2005; 112:1573-9.
79. Kostrubiec M, Pruszczyk P, Bochowicz A, Pacho R, Szulc M, Kaczynska A, et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26:2166-72.
80. Kucher N, Printzen G, Doernhoefer T, Windecker S, Meier B, Hess OM. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107:1576-8.
81. Logeart D, Lecuyer L, Thabut G, Tabet JY, Tartiere JM, Chavelas C, et al. Biomarker-based strategy for screening right ventricular dysfunction in patients with nonmassive pulmonary embolism. Intensive Care Med 2007; 33:286-92.
82. Ray P, Maziere F, Medimagh S, Lefort Y, Arthaud M, Duguet A, et al Evaluation of B-type natriuretic peptide to predict complicated pulmonary embolism in patients aged 65 years and older: Brief report. Am J Emerg Med 2006; 24:603-7.
83. Maziere F, Birolleau S, Medimagh S, Arthaud M, Bennaceur M, Riou B, et al. Comparison of troponin I and N-terminal-pro B-type natriuretic peptide for risk stratification in patients with pulmonary embolism. Eur J Emerg Med 2007; 14:207-11.